Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.
Aminah JatoiFang-Shu OuDaniel H AhnTyler J ZemlaJennifer G Le-RademacherPatrick BolandKristen K CiomborNisha L JacobsBoris PascheJames M ClearyJeannine S McCuneKatrina S PedersenAfsaneh BarziE Gabriela ChioreanErica N HeyingHeinz-Josef LenzJeff A SloanAxel GrotheyMario E LacoutureTanios Bekaii-SaabPublished in: The oncologist (2021)
Regorafenib causes hand-foot skin reactions. Preemptive clobetasol, a high-potency topical corticosteroid, appears to lessen the severity of this adverse event. Although further study is needed, the favorable adverse event profile of this intervention might prompt clinicians to discuss this option with their patients.
Keyphrases
- end stage renal disease
- wound healing
- randomized controlled trial
- chronic kidney disease
- ejection fraction
- newly diagnosed
- clinical trial
- prognostic factors
- metastatic colorectal cancer
- study protocol
- palliative care
- peritoneal dialysis
- adverse drug
- high glucose
- emergency department
- endothelial cells
- diabetic rats
- drug induced
- patient reported
- open label
- electronic health record